SAN

83.2

+1.19%↑

MRK1

113.55

+0.98%↑

SHL.DE

47.09

-0.11%↓

FRE

42.5

+0.97%↑

ONC.US

254.32

-4.58%↓

SAN

83.2

+1.19%↑

MRK1

113.55

+0.98%↑

SHL.DE

47.09

-0.11%↓

FRE

42.5

+0.97%↑

ONC.US

254.32

-4.58%↓

SAN

83.2

+1.19%↑

MRK1

113.55

+0.98%↑

SHL.DE

47.09

-0.11%↓

FRE

42.5

+0.97%↑

ONC.US

254.32

-4.58%↓

SAN

83.2

+1.19%↑

MRK1

113.55

+0.98%↑

SHL.DE

47.09

-0.11%↓

FRE

42.5

+0.97%↑

ONC.US

254.32

-4.58%↓

SAN

83.2

+1.19%↑

MRK1

113.55

+0.98%↑

SHL.DE

47.09

-0.11%↓

FRE

42.5

+0.97%↑

ONC.US

254.32

-4.58%↓

Search

Argenx SE

Abierto

SectorSanidad

480.7 0.04

Resumen

Variación precio

24h

Actual

Mínimo

475

Máximo

482.5

Métricas clave

By Trading Economics

Ingresos

-666M

169M

Ventas

-513M

791M

P/B

Media del Sector

33.106

50.291

BPA

2.273

Margen de beneficios

21.433

Empleados

1,599

EBITDA

37M

126M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

-2.07% downside

Dividendos

By Dow Jones

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-7.6B

29B

Apertura anterior

480.66

Cierre anterior

480.7

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

154 / 380 Clasificación en Healthcare

Argenx SE Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 abr 2025, 23:44 UTC

Acciones populares

Stocks to Watch: Jacobs Solutions, Argenx

10 abr 2025, 23:39 UTC

Principales Movimientos del Mercado

Argenx ADRs Gain, FDA Approves New Delivery Method of Existing Autoimmune Disease Treatment

Comparación entre iguales

Cambio de precio

Argenx SE previsión

Precio Objetivo

By TipRanks

-2.07% descenso

Estimación a 12 Meses

Media 438.33 EUR  -2.07%

Máximo 545 EUR

Mínimo 223 EUR

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Argenx SE Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

5

Comprar

0

Mantener

1

Vender

Sentimiento

By Acuity

154 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.